Ethigen's AL-721 to be renamed
Executive Summary
Egg lecithin nutritional supplement, current under evaluation at NIH as a potential AIDS therapy, will be renamed by Ethigen "to end confusion created by bootleggers selling imitation products," firm reports in press release. FDA has asked the company to rename its nutritional product in order to avoid an implied drug claim. The new name has not yet been selected.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.